Early Prediction of Gestational Diabetes in High-risk Women Based on Breath Metabolomics
Launched by TIANJIN CENTRAL HOSPITAL OF GYNECOLOGY OBSTETRICS · Dec 23, 2024
Trial Information
Current as of June 26, 2025
Enrolling by invitation
Keywords
ClinConnect Summary
This clinical trial is looking at how we can use breath samples to identify gestational diabetes early in women who are at high risk. Gestational diabetes is a condition that can occur during pregnancy and may affect both the mother and the baby. The researchers want to find new breath markers that can signal the presence of this condition and use advanced computer models to help predict it. This study will involve women aged 18 to 55 who are between 11 and 14 weeks pregnant and have at least one risk factor for gestational diabetes, such as being overweight or having a family history of diabetes.
Participants in this trial will be asked to provide breath samples and will need to agree to participate by signing a consent form. It's important to note that women who have certain health conditions, like diabetes before pregnancy or severe lung diseases, cannot take part in this study. While the trial is not yet recruiting participants, those who are eligible will have the opportunity to contribute to important research that could help improve the health of mothers and babies in the future.
Gender
FEMALE
Eligibility criteria
- • Eligibility Criteria
- • 18-55 years old
- • 11-14 weeks of pregnancy
- • at least one risk factor for GDM
- • signed a written informed consent
- Exclusion Criteria:
- • Diabetes mellitus or abnormal glucose metabolism before pregnancy
- • Hyperemesis gravidarum (urine ketone positive))
- • Thyroid dysfunction
- • Asthmatic patients
- • Hypertensive diseases that are difficult to control
- • Severe hepatic and renal insufficiency or severe electrolyte disturbance
- • Malignant tumor
- • Acute inflammation
- • lung disease
- • Patients with gastritis, duodenum and other digestive system diseases
- • Those with upper respiratory or oral problems who cannot cooperate with expiratory collection
- • smoker
About Tianjin Central Hospital Of Gynecology Obstetrics
Tianjin Central Hospital of Gynecology and Obstetrics is a leading medical institution in China, dedicated to advancing women's health through comprehensive clinical services, research, and education. As a prominent sponsor of clinical trials, the hospital focuses on innovative approaches to gynecological and obstetric care, aiming to enhance patient outcomes and contribute to the global medical community. With a team of experienced healthcare professionals and state-of-the-art facilities, the hospital is committed to conducting rigorous clinical research that adheres to the highest ethical and scientific standards, ensuring the safety and well-being of participants while striving to translate findings into effective treatment options.
Contacts
Jennifer Cobb
Immunology at National Institute of Allergy and Infectious Diseases (NIAID)
Locations
Tianjin, , China
Patients applied
Timeline
First submit
Trial launched
Trial updated
Estimated completion
Not reported